



(51) International Patent Classification:

C07K 16/00 (2006.01) G01N 33/53 (2006.01)

C07K 16/28 (2006.01) G01N 33/68 (2006.01)

(21) International Application Number:

PCT/US2019/041203

(22) International Filing Date:

10 July 2019 (10.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/695,988 10 July 2018 (10.07.2018) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).(72) Inventors: **SUMNER, Giane**; 10 Cobbler Lane, Mahwah, New Jersey 07430 (US). **CHEN, Jihua**; 3 Terrich Court, Ossining, New York 10562 (US). **PARTRIDGE, Michael**; 60 Fairway Drive, Eastchester, New York 10709 (US). **TORRI, Albert**; 32 Dolly Lane, LaGrangeville, New York12540 (US). **RAJADHYAKSHA, Manoj**; 32 Nutmeg Circle, Colchester, Connecticut 06415 (US).(74) Agent: **PAVAO, Matthew** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISTING INTERACTIONS




FIG. 4

(57) Abstract: The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*